-
EP3880172
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3880172
| EP3880172 - RESPIRABLE POLYNUCLEOTIDE POWDER FORMULATIONS FOR INHALATION [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 13.10.2023 Database last updated on 13.11.2024 | |
| Former | Request for examination was made Status updated on 20.08.2021 | ||
| Former | The international publication has been made Status updated on 22.05.2020 | ||
| Former | unknown Status updated on 18.12.2019 | Most recent event Tooltip | 30.07.2024 | New entry: Decision on request for further processing | Applicant(s) | For all designated states Civitas Therapeutics, Inc. 420 Saw Mill River Road Ardsley, NY 10502 / US | [2021/38] | Inventor(s) | 01 /
HARTMAN, Adam 66 Marshall St., Apt. 2 Medford, MA 02155 / US | 02 /
GILANI, Fahad 117 West Plain St. Wayland, MA 01778 / US | 03 /
LAVIGNE, Kyle 22 Davis Farm Road Ashland, MA 01721 / US | 04 /
LIPP, Michael M. 45A Flanagan Drive Framingham, MA 01701 / US | [2021/38] | Representative(s) | Lee, Nicholas John, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB | [2021/38] | Application number, filing date | 19817484.9 | 13.11.2019 | [2021/38] | WO2019US61237 | Priority number, date | US201862760232P | 13.11.2018 Original published format: US 201862760232 P | [2021/38] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020102394 | Date: | 22.05.2020 | Language: | EN | [2020/21] | Type: | A1 Application with search report | No.: | EP3880172 | Date: | 22.09.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 22.05.2020 takes the place of the publication of the European patent application. | [2021/38] | Search report(s) | International search report - published on: | EP | 22.05.2020 | Classification | IPC: | A61K9/00, A61P11/00, A61K9/16 | [2021/38] | CPC: |
A61K9/0075 (EP);
A61K31/7105 (US);
A61K9/1611 (EP,US);
A61K9/1617 (EP);
A61K9/1623 (EP,US);
A61K9/1641 (EP);
A61P11/00 (EP)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/38] | Extension states | BA | 09.06.2021 | ME | 09.06.2021 | Title | German: | LUNGENGÄNGIGE POLYNUKLEOTIDPULVERFORMULIERUNGEN ZUR INHALATION | [2021/38] | English: | RESPIRABLE POLYNUCLEOTIDE POWDER FORMULATIONS FOR INHALATION | [2021/38] | French: | FORMULATIONS DE POUDRE DE POLYNUCLÉOTIDES RESPIRABLES À INHALER | [2021/38] | Entry into regional phase | 09.06.2021 | National basic fee paid | 09.06.2021 | Designation fee(s) paid | 09.06.2021 | Examination fee paid | Examination procedure | 09.06.2021 | Amendment by applicant (claims and/or description) | 09.06.2021 | Examination requested [2021/38] | 09.06.2021 | Date on which the examining division has become responsible | 17.10.2023 | Despatch of a communication from the examining division (Time limit: M06) | 23.05.2024 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 19.07.2024 | Reply to a communication from the examining division | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 19.07.2024 | Request for further processing filed | 19.07.2024 | Full payment received (date of receipt of payment) Request granted | 29.07.2024 | Decision despatched | Fees paid | Renewal fee | 09.06.2021 | Renewal fee patent year 03 | 13.10.2022 | Renewal fee patent year 04 | 15.11.2023 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]WO2009027337 (NOVARTIS AG [CH], et al) [X] 1-6,8-15 * page 9, line 1 - page 10, line 17 * * page 20, lines 9-20 * * examples 1B, 1C, 2-5, 7E, 7F, 8-14 *; | [XY]US2011077284 (BRITO LUIS [US], et al) [X] 1-5,8,9,11-15 * page 2, paragraph 0023 - page 3, paragraph 0028 * * page 3, paragraph 0044 - page 4, paragraph 0045 * * page 11, paragraph 0143 * * examples 4-12 * [Y] 7; | [Y]US2016317503 (LIPP MICHAEL M [US]) [Y] 7 * page 2, paragraph 0033 - page 3, paragraph 0043 * * page 3, paragraphs 0048-0049 * * example - ** claim - * | by applicant | - GUSTAFSSON et al., "Codon bias and heterologous protein expression", Trends Biotechnol, (20040000), vol. 22, pages 346 - 53 | - VILLALOBOS et al., "Gene Designer: a synthetic biology tool for constructing artificial DNA segments", BMC Bioinformatics, (20060000), vol. 7, doi:10.1186/1471-2105-7-285, page 285, XP021013796 DOI: http://dx.doi.org/10.1186/1471-2105-7-285 | - CARILLO, H.LIPMAN, D., SIAM J AppliedMath., (19880000), vol. 48, page 1073 | - DEVEREUX, J. et al., Nucleic Acids Research, (19840000), vol. 12, no. 1, page 387 | - ALTSCHUL, S. F. et al., J. Molec. Biol., (19900000), vol. 215, page 403 | - United States Pharmacopia convention, (19990000), pages 4950 - 4951 | - JEMIELITY, J. et al., RNA, (20030000), vol. 9, pages 1108 - 1122 |